GET DAILY SIGNALSBioVie (BIVI) Climbs +15.7% Over the Past 30 Days
Key Takeaways
- BIVI shares have climbed roughly 15.7% over the trailing 30 days, rising from about $1.46 in early October to near $1.69.
- The gain follows a sharp mid-October slide toward $1.13 and a subsequent rebound tied to a wave of bezisterim clinical-data news.
- BioVie is a clinical-stage biotech with no product revenue, so its share price is driven primarily by clinical catalysts and financing developments.
- Recent momentum was supported by bezisterim data in Parkinson's disease and Long COVID, an NIH workshop invitation, and a late-breaking presentation selection.
- Over the trailing quarter the stock is roughly flat, masking a spike to an intraday high of $3.79 and a dip to an intraday low of $0.82.
- A going-concern disclosure and ongoing dilution risk remain key offsets to the company's clinical narrative.
- For additional detail, explore BIVI's Price Targets, Earnings, and Forecasts on Tickeron's dedicated pages.
- Discover automated strategies by exploring Trending AI Robots.
BioVie (BIVI) Company Overview and Market Position
BioVie Inc. is a clinical-stage biopharmaceutical company developing drug therapies for neurological and neurodegenerative disorders and advanced liver disease. Its lead program, bezisterim, is an orally administered small molecule being evaluated in Phase 3 for mild-to-moderate Alzheimer's disease, in Phase 2b for Parkinson's disease, and in a Long COVID program. The company's second asset, BIV201 (terlipressin), is in Phase 3 testing for life-threatening complications of liver cirrhosis and ascites and holds FDA Fast Track and Orphan Drug designations.
Headquartered in Carson City, Nevada, BioVie is a small, pre-revenue company with no approved products and limited commercialization infrastructure. Because it generates no meaningful revenue, investors follow the stock almost exclusively for binary clinical readouts, regulatory milestones, and financing events rather than traditional fundamentals. This profile makes BIVI highly sensitive to news flow and to shifts in risk appetite across the broader biotechnology sector. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
BioVie (BIVI) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, BIVI has risen roughly 15.7%, moving from a closing price of about $1.46 on October 2 to near $1.69 in early November. The path was not linear: the stock fell to roughly $1.13 by mid-October before recovering sharply as a series of clinical announcements reached investors.
The trailing-quarter picture is more muted and far more volatile. Over approximately three months, the stock is essentially flat on a net basis, but that headline conceals extreme intra-quarter swings. In August, BIVI traded as low as $0.82 intraday before surging to an intraday high of $3.79, followed by a prolonged retreat through September and October. The contrast between the calm-looking quarterly result and the stock's wide daily range underscores the outsized influence of single-session news events on this micro-cap name.
What Drove BIVI Stock Price in the Last 30 Days
The 30-day advance was fueled largely by a concentrated stretch of bezisterim-related news. In late October, BioVie presented results from the Phase 2 SUNRISE-PD trial in early Parkinson's disease at the American Neurological Association annual meeting, reporting statistically significant improvements in both motor and non-motor symptoms among patients with elevated baseline inflammation, compared with placebo. The company also presented Phase 2 ADDRESS-LC data evaluating bezisterim in Long COVID.
Momentum continued with an invitation to present bezisterim Long COVID data at the National Institutes of Health's RECOVER-TLC workshop in late October, followed by the announcement that BioVie had been selected for a late-breaking oral presentation of bezisterim Long COVID data at the 4th Long COVID International Conference. These data-driven catalysts helped reverse the stock's mid-October decline.
Offsetting factors remained present throughout the period. A September financing agreement and related prospectus, together with the company's earlier going-concern disclosure, continued to weigh on sentiment and contributed to the slide toward the mid-October low before the clinical headlines drove the rebound.
What Drove BIVI Stock Performance Over the Last Quarter
The trailing quarter was defined by exceptional volatility rather than a single directional trend. In early August, the stock experienced a rapid selloff to an intraday low of $0.82, followed days later by a dramatic spike to an intraday high of $3.79 on extraordinarily heavy volume. BioVie filed its annual report for the fiscal year ended June 30 in mid-August, which included a going-concern disclosure reflecting substantial doubt about the company's ability to continue as a going concern absent additional capital.
Through September and October, the stock generally drifted lower as investors weighed financing needs, dilution risk, and the company's cash position against a clinical pipeline that still lacks approved products. The late-quarter recovery into early November was driven primarily by the renewed cadence of bezisterim data presentations rather than by any change in the company's underlying financial profile.
BIVI Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important variables for BIVI are clinical and financial. Investors will likely focus on the next quarterly earnings report, expected in November 2026, for updates on cash runway, operating expenses, and any financing plans. Continued bezisterim data disclosures, including longer-term Parkinson's and Long COVID results, and progress toward the Phase 3 Alzheimer's program, remain central to the investment thesis.
Regulatory and development milestones for BIV201 in liver cirrhosis and ascites also carry weight. Financial risks, including the going-concern disclosure, potential future equity raises, and shareholder dilution, are material and could pressure the stock regardless of positive clinical news. Broader biotechnology sentiment and interest-rate expectations may likewise influence a small-cap, pre-revenue name such as BIVI. A limited analyst following currently assigns an average rating of Strong Buy with a 12-month price target near $5.26, though such targets carry substantial uncertainty for a clinical-stage company. From what I see, monitoring these elements closely will be key.
Exploring Tickeron’s Trending AI Robots
In my own research process, I often look at Tickeron’s Trending AI Robots page to get a quick view of automated strategies that are gaining traction across the platform. It highlights a curated selection of AI-driven trading bots drawn from hundreds of bots trading thousands of tickers, with only top-performing and most relevant ones featured. These bots cover a range of strategies, timeframes, and risk profiles, offering a practical starting point for anyone interested in rules-based approaches. The page makes it straightforward to review current options and see how they might align with different objectives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BIVI in upward trend: price rose above 50-day moving average on November 03, 2026
BIVI moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 33 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BIVI's RSI Oscillator exited the oversold zone, 27 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on BIVI as a result. In 69 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for BIVI just turned positive on October 21, 2026. Looking at past instances where BIVI's MACD turned positive, the stock continued to rise in 37 of 45 cases over the following month. The odds of a continued upward trend are 82%.
Following a +9.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIVI advanced for three days, in 194 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 51 cases where BIVI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
BIVI broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BIVI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.437) is normal, around the industry mean (3.051). P/E Ratio (-0.567) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. BIVI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIVI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement